Search

Schrodinger Inc

Suletud

SektorTervishoid

15.03 -1.89

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

14.93

Max

15.29

Põhinäitajad

By Trading Economics

Sissetulek

-196M

-60M

Müük

-29M

59M

Aktsiakasum

-0.62

Kasumimarginaal

-102.456

Töötajad

850

EBITDA

-94M

-58M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+32.7% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

5. aug 2026

Turustatistika

By TradingEconomics

Turukapital

262M

1.2B

Eelmine avamishind

16.92

Eelmine sulgemishind

15.03

Uudiste sentiment

By Acuity

55%

45%

274 / 340 Pingereas Healthcare

Schrodinger Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

20. juuli 2026, 15:12 UTC

Correlated Moves

Schrodinger Inc. shares are lower amid a decline in the ARK Genomic Revolution ETF and broader market pressures, despite a slight rebound earlier in the session.

Võrdlus sarnastega

Hinnamuutus

Schrodinger Inc Prognoos

Hinnasiht

By TipRanks

32.7% tõus

12 kuu keskmine prognoos

Keskmine 20.33 USD  32.7%

Kõrge 24 USD

Madal 17 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Schrodinger Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

5 ratings

4

Osta

1

Hoia

0

Müü

Sentiment

By Acuity

274 / 340 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Schrodinger Inc

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
help-icon Live chat